[go: up one dir, main page]

DK2515928T3 - Oxyntomodulin peptidanalog - Google Patents

Oxyntomodulin peptidanalog

Info

Publication number
DK2515928T3
DK2515928T3 DK10801033.1T DK10801033T DK2515928T3 DK 2515928 T3 DK2515928 T3 DK 2515928T3 DK 10801033 T DK10801033 T DK 10801033T DK 2515928 T3 DK2515928 T3 DK 2515928T3
Authority
DK
Denmark
Prior art keywords
peptid
oxyntomodulin
analog
peptid analog
oxyntomodulin peptid
Prior art date
Application number
DK10801033.1T
Other languages
English (en)
Inventor
Jorge Alsina-Fernandez
Wayne David Kohn
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43587001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2515928(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK2515928T3 publication Critical patent/DK2515928T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/605Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
DK10801033.1T 2009-12-22 2010-12-15 Oxyntomodulin peptidanalog DK2515928T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28888809P 2009-12-22 2009-12-22
US35257610P 2010-06-08 2010-06-08
PCT/US2010/060390 WO2011087672A1 (en) 2009-12-22 2010-12-15 Oxyntomodulin peptide analogue

Publications (1)

Publication Number Publication Date
DK2515928T3 true DK2515928T3 (da) 2014-08-25

Family

ID=43587001

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10801033.1T DK2515928T3 (da) 2009-12-22 2010-12-15 Oxyntomodulin peptidanalog

Country Status (35)

Country Link
US (1) US8367607B2 (da)
EP (1) EP2515928B1 (da)
JP (1) JP5717759B2 (da)
KR (1) KR101399671B1 (da)
CN (1) CN102740873B (da)
AR (1) AR079345A1 (da)
AU (1) AU2010341651B2 (da)
BR (1) BR112012017348B1 (da)
CA (1) CA2784671C (da)
CL (1) CL2012001686A1 (da)
CO (1) CO6551738A2 (da)
CR (1) CR20120338A (da)
DK (1) DK2515928T3 (da)
DO (1) DOP2012000176A (da)
EA (1) EA022820B1 (da)
ES (1) ES2486675T3 (da)
HK (1) HK1170941A1 (da)
HN (1) HN2012001321A (da)
HR (1) HRP20140616T1 (da)
IL (1) IL220161B (da)
JO (1) JO2976B1 (da)
MA (1) MA33825B1 (da)
MX (1) MX2012007438A (da)
MY (1) MY160773A (da)
NZ (1) NZ600731A (da)
PE (1) PE20121393A1 (da)
PH (1) PH12012501263B1 (da)
PL (1) PL2515928T3 (da)
PT (1) PT2515928E (da)
RS (1) RS53505B1 (da)
SG (1) SG181430A1 (da)
SI (1) SI2515928T1 (da)
TN (1) TN2012000302A1 (da)
TW (1) TWI423812B (da)
WO (1) WO2011087672A1 (da)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
CA2913805A1 (en) 2005-11-07 2007-05-18 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
CN101453982B (zh) 2006-05-30 2011-05-04 精达制药公司 两件式内部通道渗透递送系统流动调节器
DK2359808T3 (da) 2006-08-09 2013-08-05 Intarcia Therapeutics Inc Osmotiske leveringssystemer og stempelaggregater
US8454971B2 (en) 2007-02-15 2013-06-04 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
CA2707861A1 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Glucagon antagonists
AU2008318876B2 (en) 2007-10-30 2014-05-15 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and GLP-1 agonist activity
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
PE20100056A1 (es) 2008-06-17 2010-01-26 Univ Indiana Res & Tech Corp Analogos de glucagon como agonistas gip
AU2009327418A1 (en) 2008-12-19 2010-06-24 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
EP2443146B1 (en) 2009-06-16 2016-10-05 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
DK2462246T3 (da) 2009-09-28 2017-11-06 Intarcia Therapeutics Inc Hurtig etablering og/eller afslutning af væsentlig steady-state-lægemiddelafgivelse
CN102834108A (zh) 2010-01-27 2012-12-19 印第安纳大学研究及科技有限公司 用于治疗代谢紊乱和肥胖症的胰高血糖素拮抗剂-gip激动剂偶联物和组合物
MX2012013005A (es) 2010-05-13 2013-02-26 Univ Indiana Res & Tech Corp Peptidos de la superfamilia de glucagon que presentan actividad del receptor acoplado a proteinas g.
MX2012013001A (es) 2010-05-13 2013-02-26 Univ Indiana Res & Tech Corp Peptidos de la superfamilia de glucagon que presentan actividad del receptor nuclear de hormonas.
MX2013006304A (es) 2010-12-22 2013-07-02 Univ Indiana Res & Tech Corp Analogos de glucagon que exhiben actividad del receptor gip.
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US10166295B2 (en) 2011-06-02 2019-01-01 Opko Biologics Ltd. Pegylated OXM variants
LT2718318T (lt) 2011-06-10 2018-10-25 Hanmi Science Co., Ltd. Nauji oksintomodulino dariniai ir farmacinė kompozicija, apimanti šiuos darinius, nutukimo gydymui
SG195275A1 (en) 2011-06-17 2013-12-30 Hanmi Science Co Ltd A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
LT2723367T (lt) 2011-06-22 2017-08-25 Indiana University Research And Technology Corporation Bendri gliukagono/glp-1 receptoriaus agonistai
RU2014101697A (ru) 2011-06-22 2015-07-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Коагонисты рецепторов глюкагона/glp-1
ES2672880T3 (es) 2011-11-17 2018-06-18 Indiana University Research And Technology Corporation Péptidos de la superfamilia de glucagón que muestran actividad de receptor de glucocorticoides
CN104487082A (zh) 2012-04-19 2015-04-01 奥普科生物制品有限公司 长效胃泌酸调节素变体及其生产方法
CA2875599C (en) 2012-06-04 2020-08-18 Opko Biologics Ltd. Pegylated oxyntomodulin variants
AR091477A1 (es) 2012-06-21 2015-02-04 Univ Indiana Res & Tech Corp Analogos de glucagon que presentan actividad de receptor de gip
KR101968344B1 (ko) * 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
KR101993393B1 (ko) * 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
KR102311517B1 (ko) 2012-11-06 2021-10-14 한미약품 주식회사 옥신토모듈린과 면역글로불린 단편을 포함하는 단백질 결합체의 액상 제제
CN105121459A (zh) 2012-11-20 2015-12-02 奥普科生物制品有限公司 通过连接至促性腺激素羧基端肽来增加多肽的流体动力学体积的方法
CA2894765A1 (en) 2012-12-21 2014-06-26 Sanofi Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重glp-1/升糖素受體促效劑
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽-4(exendin-4)胜肽類似物
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重glp-1/gip受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自exendin-4之雙重glp-1/升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
TWI772252B (zh) 2014-09-16 2022-08-01 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
EP3302354B1 (en) 2015-06-03 2023-10-04 i2o Therapeutics, Inc. Implant placement systems
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198628A1 (en) 2015-06-12 2016-12-15 Sanofi Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
CN108289851B (zh) 2015-06-19 2021-06-01 Opko生物科学有限公司 长效凝固因子及其产生方法
TWI783244B (zh) 2015-06-22 2022-11-11 美商美國禮來大藥廠 升糖素及glp-1共激動劑化合物
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
MA53353A (fr) 2016-05-16 2021-06-09 Intarcia Therapeutics Inc Polypeptides sélectifs pour le récepteur du glucagon et méthodes pour leur utilisation
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
US20190160152A1 (en) 2016-06-09 2019-05-30 Opko Biologics Ltd. Long-acting oxyntomodulin formulation and methods of producing and administering same
CA3030533A1 (en) 2016-07-11 2018-01-18 Oren HERSHKOVITZ Long-acting coagulation factor vii and methods of producing same
TW201832783A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 包含glp-1/胰高血糖素雙重激動劑、連接子和透明質酸的接合物
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
CN108299553B (zh) * 2017-01-13 2021-07-16 博瑞生物医药(苏州)股份有限公司 胃泌酸调节素修饰物
KR101990075B1 (ko) * 2018-07-19 2019-06-18 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 비만 예방 또는 치료용 약학 조성물
KR20200135618A (ko) * 2019-05-23 2020-12-03 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 비알코올성 지방간 질환의 예방 또는 치료용 약학 조성물
MX2021000291A (es) 2018-07-19 2021-03-31 D&D Pharmatech Inc Composicion farmaceutica que comprende polipeptido.
US20200262887A1 (en) 2018-11-30 2020-08-20 Opko Ireland Global Holdings, Ltd. Oxyntomodulin peptide analog formulations

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5445090A (en) 1991-07-25 1995-08-29 Mim Industries, Inc. Interchangeable clamp for use in a sewing machine
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
CA2204645A1 (en) * 1994-11-07 1996-05-17 Keiichi Yano Novel oxyntomodulin
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
PT1411075E (pt) 1998-03-12 2008-08-05 Nektar Therapeutics Al Corp Método para a preparação de conjugados de polímeros
DE60026073T2 (de) 1999-12-22 2006-09-28 Nektar Therapeutics Al, Corp., Huntsville Sterisch gehinderte derivate von wasserlöslichen polymeren
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US6436386B1 (en) 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
SI1605897T1 (sl) 2003-03-19 2012-11-30 Lilly Co Eli Polietilen glikol povezane GLP spojine
ME02786B (me) 2005-05-13 2011-10-31 Lilly Co Eli Glp-1 pegilovana jedinjenja
GB0511986D0 (en) * 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
DK1891105T3 (da) * 2005-06-13 2012-07-16 Imp Innovations Ltd Hidtil ukendte forbindelser og deres påvirkninger på spiseadfærd
CA2913805A1 (en) 2005-11-07 2007-05-18 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
EP2471811B1 (en) * 2006-02-22 2015-09-16 Merck Sharp & Dohme Corp. Oxyntomodulin derivatives
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
US8454971B2 (en) 2007-02-15 2013-06-04 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US7994122B2 (en) 2007-06-15 2011-08-09 Zealand Pharma A/S Glucagon analogues
ES2532116T3 (es) * 2007-09-05 2015-03-24 Novo Nordisk A/S Péptidos derivados con A-B-C-D y sus usos terapéuticos
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
AR079344A1 (es) * 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad

Also Published As

Publication number Publication date
PL2515928T3 (pl) 2014-11-28
DOP2012000176A (es) 2012-08-31
KR20120096022A (ko) 2012-08-29
WO2011087672A1 (en) 2011-07-21
CN102740873B (zh) 2014-11-05
CA2784671A1 (en) 2011-07-21
JP2013515057A (ja) 2013-05-02
BR112012017348B1 (pt) 2019-11-05
TN2012000302A1 (en) 2013-12-12
MY160773A (en) 2017-03-15
MA33825B1 (fr) 2012-12-03
TW201143793A (en) 2011-12-16
MX2012007438A (es) 2012-07-17
SI2515928T1 (sl) 2014-08-29
US20110152182A1 (en) 2011-06-23
RS53505B1 (en) 2015-02-27
IL220161A0 (en) 2012-07-31
SG181430A1 (en) 2012-07-30
NZ600731A (en) 2014-06-27
CO6551738A2 (es) 2012-10-31
ES2486675T3 (es) 2014-08-19
JP5717759B2 (ja) 2015-05-13
HN2012001321A (es) 2015-08-31
PH12012501263B1 (en) 2018-08-31
CN102740873A (zh) 2012-10-17
CA2784671C (en) 2015-06-16
AU2010341651A1 (en) 2012-06-07
EP2515928B1 (en) 2014-06-18
EP2515928A1 (en) 2012-10-31
US8367607B2 (en) 2013-02-05
PH12012501263A1 (en) 2013-02-04
CR20120338A (es) 2012-07-23
HRP20140616T1 (hr) 2014-08-15
BR112012017348A2 (pt) 2017-01-10
EA201290549A1 (ru) 2013-01-30
JO2976B1 (en) 2016-03-15
AR079345A1 (es) 2012-01-18
TWI423812B (zh) 2014-01-21
AU2010341651B2 (en) 2014-01-16
EA022820B1 (ru) 2016-03-31
HK1170941A1 (en) 2013-03-15
PE20121393A1 (es) 2012-10-26
CL2012001686A1 (es) 2012-11-23
IL220161B (en) 2018-12-31
PT2515928E (pt) 2014-09-03
KR101399671B1 (ko) 2014-05-27

Similar Documents

Publication Publication Date Title
DK2515928T3 (da) Oxyntomodulin peptidanalog
HK1170943A1 (en) Oxyntomodulin peptide analogue
BRPI1009315A2 (pt) agentes anti-inflamatórios
DK2398483T3 (da) Oxyntomodulinanaloge
DK3097925T3 (da) Farmaceutisk sammensætning
BRPI1004940A2 (pt) composição farmacêutica
DK3620518T3 (da) Amylasepolypeptid
BRPI1015939A2 (pt) composição farmacêutica
ATE546999T1 (de) Feldspritze
BRPI1010661A2 (pt) peptídeo
EP2460523A4 (en) TABLET
BRPI0910722A2 (pt) columbário
DOP2011000348A (es) Construcciones casb7439
BR112012003149A2 (pt) composição farmacêutica
DOP2011000242A (es) Macrolido anti-inflamatorio
IT1395137B1 (it) Nuovi peptidi antipatogeni
FI20096108L (fi) Järjestely
SE0900379L (sv) Benstöd
IT1393297B1 (it) Disposizione funeraria
EP2498660A4 (en) Squeegee assembly
ES1070798Y (es) Ataud
FR2946942B1 (fr) Comble-lacune retractable
FR2946992B1 (fr) Columbarium
TH104932B (th) ศาลา
ES1070645Y (es) Colgante